PEG Glucocerebrosidase


Return to contents page


Dr Edward Ginns, National Institutes of Health, Washington talked about PEG glucocerebrosidase at the NGF Conference held in Philadelphia in November 1994.

He said that the modification of glucocerebrosidase with polyethylene glycol (PEG) allows it to remain longer in the blood so it can clear lipids (glucocerebroside) from the blood rather than just from the macrophages. This should allow less frequent and dramatically smaller doses. In mice, PEG glucocerebrosidase lasts hours to days in the blood compared with 8 to 25 minutes for Ceredase (Editor's note: Ceredase remains longer in the organs).

Dr Ginns expects the PEG product. to create fewer antibodies. In August 1994 the FDA approved a protocol for clinical trials which are planned to start shortly after patients are recruited.

For further information contact Dr Ginns through Ms Elisabeth Alzona at Clinical Neuroscience Branch, NIMH, National Institute of Health, Building 49, Room B1EE16, 9000 Rockville Pike, Bethesda, MD 20892, USA. Tel: (0l01) 301 496 0373.


Return to contents page